Genome-wide association studies (GWAS) are a powerful way to identify disease susceptibility variants 1, 2 . However, the molecular bases of the observed associations often remain unclear because the markers used merely serve as indicators that a causative variant is present nearby. Pinpointing these changes is a major challenge in unravelling the genetic basis of complex disease predisposition.
The SNP rs6983267 at chromosome 8q24.21 has been implicated in predisposition to colorectal (CRC) and prostate cancer [3] [4] [5] [6] [7] . The CRC association has been confirmed in several studies [8] [9] [10] [11] [12] . The risk extends also to benign colonic adenomas, indicating that the causative variant already has a role at the precancerous stage 3, 13 . The risk allele G is common, with an allele frequency of 50% in individuals of European descent and almost 100% in populations with African origin 5 . Thus, although the increase in CRC risk is modest (approximately 1.5-fold in GG homozygotes 3, 10 ), the contribution of rs6983267 to CRC incidence globally is extremely important.
The mechanism by which this SNP increases risk of CRC has not been elucidated, and resequencing of the region has not revealed obvious pathogenic changes 14 . The nearest protein-coding gene, MYC, resides 335 kb downstream from rs6983267; hence, one hypothesis has been that the SNP might be in linkage disequilibrium (LD) with unknown elements controlling the expression of this key oncogene. Possible existence of a regulatory region at rs6983267 has been proposed according to the UCSC genome browser, which indicates that this region is highly conserved during evolution, and the VISTA enhancer database, which predicts a putative enhancer in the region (see URLs section in Online Methods) 14 . The vicinity of MYC is of interest as this gene is a major CRC oncogene and one of the most well-established targets of Wnt signaling pathway 15 . The Wnt signaling pathway is aberrantly activated in over 90% of CRCs, most commonly through mutations in the APC (adenomatous polyposis coli) gene 16 . In the absence of Wnt ligand, APC participates in the degradation of the central cytoplasmic signal transducer of the Wnt pathway, b-catenin. Binding of Wnt proteins to their receptors on the cell surface results in stabilization of b-catenin, which enters the nucleus and functions as cofactor for transcription factors of the TCF (T-cell factor)/LEF (lymphoid enhancer factor) family. Tumor-promoting mutations inactivating APC hamper degradation of b-catenin and lead to constitutive ligand-independent activation of TCF/LEFmediated transcription. Germline variants affecting responsiveness of key enhancer elements to TCF/LEF could play an important role in CRC susceptibility.
We have previously shown that somatically emerging allelic imbalance at rs6983267 in tumor DNA favors the G risk allele 10 . We did not examine whether the imbalance is due to loss of the nonrisk T allele or gain of the risk G allele. The former would be compatible with the classical tumor suppressor mechanism typically seen in highpenetrance hereditary CRC syndromes, whereas the latter would suggest an oncogenic change. In the present study, we aimed to shed light to the mechanisms that underlie CRC susceptibility associated with rs6983267.
RESULTS

Copy number analysis in CRC tumors
In our previous work 10 , we had identified 67 CRCs in which the G allele was selected for, as compared with 34 with T allele selection, showing that the G allele is favored during genesis of CRC (P ¼ 0.0007). To characterize the nature of G allele overrepresentation, we analyzed paired normal and tumor DNAs from 12 heterozygous CRC cases (Supplementary Note) showing an excess of G allele as compared with T allele in cancer DNA using the Illumina HumanCNV370-Duo SNP array. Eleven out of 12 tumors showed copy number increase of a large segment of the G allele-bearing chromosome region (typically 3 to 5 copies) (Fig. 1) . In nine tumors, the amplicon included the whole long arm of chromosome 8 (Fig. 1a) . Two samples showed gains of shorter chromosome 8 segments (Fig. 1b) . In one case, the experiment was not conclusive, although additional SNP sequencing analysis gave evidence for an imbalance spanning at least from rs10505476 (chr. 8:128,477,298 bp) to rs10505474 (chr. 8:128,486,686 bp). No cases with T-allele loss were identified, establishing copy number increase as the cause for preferred overrepresentation of the G allele in CRCs (P ¼ 0.001). This result strongly suggests that the function of the causative germline alteration is likely to be oncogenic.
Imputing and association analyses
To further investigate the 8q24 locus association and estimate the fraction of common variation at this locus, we imputed genotype data from the GWAS of Tomlinson et al. 3 . In total, 172 HapMap SNPs were successfully imputed in the interval between 128.419 Mb and 128.562 Mb at 8q24 using the Illuminagenerated SNP genotype data from CORGI (29 SNPs from the Illumina Hap550 bead array) and NSCCG1 (83 SNPs from an Illumina Infinium custom iSelect array) (Supplementary Note and Supplementary Fig. 1 ). rs6983267 showed the peak of the association signal in the combined analysis (P ¼ 1.16 Â 10 À10 ). Second to that was rs10505477 (P ¼ 6.41 Â 10 À10 ) and the third-ranked SNP was rs7014346 (P ¼ 2.47 Â 10 À7 ), identified as the top SNP at the locus by Tenesa et al. 17 . rs10505477 and rs698327 have similar allele frequency and are strongly correlated (r 2 ¼ 0.92). Owing to few recombination events within the 5.86-kb region of LD containing rs10505477 and rs693267, there are effectively two major 8q24.21 haplotypes in the disease, compatible with a single disease-causing variant tagged by rs693267. This conclusion is also compatible with data reported by Yeager et al. 14 , who resequenced the region in 79 prostate cancer cases and controls of European origin and were unable to find new potentially pathogenic variants.
Prediction of enhancer elements around MYC
To examine the nature of the putative oncogenic change at the rs6983267 region, we used the computational method Enhancer Element Locator (EEL) 18 to detect possible regulatory motifs. EEL predicts functional enhancer elements by aligning genomic regions from two different species according to the order of transcription factor binding sites that they encode. It scores the elements on the basis of transcription factor affinities and clustering and conservation of the sites (for details, see refs. 18, 19 (Fig. 1c) . The strong predicted element that contains rs6983267 was the only element predicted by EEL within the haploblock (EEL score 4 100; a cutoff that gives 417 elements per aligned gene; Supplementary Table 1 and data not shown), suggesting that rs6983267 could be the causative change.
Affinity analyses of the predicted TCF4 site Notably, EEL predicted that rs6983267 directly affected a binding site for TCF4 (also known as TCF7L2), a transcription factor activated in most CRCs 16 ( Fig. 2a and Supplementary Fig. 2 ). The TCF4 binding sequence 5¢-GATGAAAGG-3¢ identified here matches closely to the TCF4 consensus sequence CATCAAAGG 18 . We previously created a binding affinity matrix for TCF4, and according to these data the change from T to G at the last position (5¢-GATGAAAGT-3¢ to 5¢-GATGAAAGG-3¢) considerably increases the affinity of TCF4 for this site (ref. 18 and data not shown). As the TCF4 site identified here is not the exact consensus sequence, we specifically tested the affinity of the exact sequences corresponding to the T and G allele, GATGAAAGT and GATGAAAGG, and found that they bound TCF4 in vitro with sequence-specific DNA-binding affinities that are 20% and 32% of the maximal affinity site, respectively (Fig. 2b) . These affinities are well within the range reported for physiologically relevant transcription factor binding sites 21, 22 . We also conducted electrophoretic mobility shift assays (EMSA), which confirmed that the G allele has higher affinity to TCF4 than the T allele (Fig. 2c) . Another TCF4 site found in the predicted element, AATGAAAGG, has earlier been reported to have approximately 12% of maximal affinity 18 . No other conserved TCF4 sites with significant predicted activity lie within this enhancer.
The element containing rs6983267 is a Wnt-responsive enhancer To test whether the predicted element (which we refer to hitherto as MYC-335) could function as a Wnt-pathway-dependent enhancer element in cultured cells, we cloned MYC-335 elements containing the T and G alleles of rs6983267 into a reporter vector containing a minimal promoter followed by a firefly luciferase reporter gene. The promoter is inactive in the absence of enhancer activity derived from the cloned fragments and can thus be used to test whether MYC-335 has enhancer activity in cultured cells. Transfection of these vectors into Wnt-responsive HEK293T cells in the absence of Wnt induction revealed no significant change in reporter activity between the G and T allele (Fig. 2d) . However, activation of the Wnt pathway through GSK3b inhibition by lithium chloride revealed that MYC-335 has Wnt-responsive enhancer activity, and that the G allele shows 1.5-fold stronger Wnt responses than the T allele. Mutation of the second and third nucleotides of the TCF4 sites in the G and T allele reporters resulted in partial loss of Wnt responsiveness and complete loss of the effect of the SNP, indicating that the observed increase in the induction of the G allele was dependent on the TCF4 site containing rs6983267. We also mutated the other TCF4 site individually and together with the SNP-containing TCF4 site. All mutants were similar to the weaker T allele in their response to Wnt signaling, indicating that both TCF4 sites are required for the 1.5-fold increased induction in the G allele-containing reporter construct (Fig. 2d) .
The rs6983267 site is occupied by TCF4 and b-catenin in CRC cells
To assess whether the MYC-335 enhancer element is active in its normal chromosomal context in CRC cells, we conducted a chromatin immunoprecipitation (ChIP) assay (Fig. 3) . First, 12 CRC cell lines were genotyped for rs6983267. VACO5, GP5D, HCT8, DLD1/HCT15, LoVo, LS174T and LS180 are heterozygous at rs6983267, SW480, HCA7, HCT116, HUTU80 and RKO are homozygous for G and CCL-231 is homozygous for T. ChIP assays were initially done in LoVo cells using antibodies to TCF4, b-catenin and control IgG (Fig. 3a,b) . These experiments showed that the rs6983267-containing region indeed binds the DNA-binding protein TCF4 and the transcriptional activator b-catenin in vivo. Strong binding of TCF4 to the site was confirmed in all six other heterozygous cell lines tested, as well as in CCL-231 (TT) (Fig. 3c) .
Negative control regions did not show significant binding of TCF4 in any of the cell lines tested (Fig. 3a,b and data not shown).
We sequenced input and anti-TCF4 immunoprecipitated DNA, and then analyzed the signal intensity for the individual alleles (Fig. 3f,g ) 23 . This analysis on LoVo cells revealed that the risk-allele G at the site enhances TCF4 binding approximately twofold (Fig. 3f) , consistent with our earlier in vitro binding-affinity experiments (Fig. 2b) 18 . The preferential binding of the G allele to TCF4 was also observed by sequencing the TCF4 immunoprecipitated rs6983267-containing PCR product in all other cell lines heterozygous for rs6983267 (Fig. 3g) .
To further validate the MYC-335 element, we systematically identified TCF4 binding sites across the entire human genome both experimentally and computationally using chromatin immunoprecipitation by sequencing (ChIP-Seq) 24 in LoVo cells and EEL alignment 18 , respectively. Integration of these analyses identified MYC-335 as the fourthhighest ranked element containing a conserved TCF4 site in the entire human genome ( Table 1) . Nine out of ten highest-ranked elements identified were located close to known Wnt/TCF4 target genes ( Table 1) . Furthermore, ChIP-Seq in LoVo cells revealed that TCF4 binds MYC-335 stronger than any other sequence within 1 Mb of MYC (Fig. 3d) . Detailed analysis of the sequenced fragments indicated that the peak of binding is located at rs6983267, with 14 sequenced fragments containing only the TCF4 site at rs6983267 (Fig. 3e and Supplementary Fig. 3 ). Ten sequenced fragments (Supplementary Fig. 3 ) contained only the weaker TCF4 site located 106 bp downstream (Fig. 2a, asterisk) , suggesting that, consistent with the luciferase reporter analyses, this site is also occupied in CRC cells. Strong binding of TCF4 to the SNP region was similarly detected in another colon cancer cell line, GP5D, using ChIP-seq ( Supplementary  Fig. 4 ). Furthermore, in both LoVo and GP5D cells, the region near rs6983267 was also enriched in lysine 4 monomethylated histone H3 (data not shown), a known marker for enhancer elements 25 .
MYC-335 functions as a tissue-specific enhancer in vivo
To test whether the MYC-335 element also functions as an enhancer element in vivo, we cloned the element in front of a LacZ reporter gene and injected the construct into mouse oocytes. In the resulting embryos, MYC-335 drove LacZ expression in the tail and/or limbs at embryonic day 12.5 (E12.5) in seven of eight embryos with LacZ staining, verifying the functionality of the element in vivo. The observed expression pattern is consistent with that of Wnt signaling target genes 26, 27 (Fig. 4, left embryo) . Consistently, we observed only ectopic LacZ staining in embryos injected with a construct where the two conserved TCF4 sites in MYC-335 (Fig. 2a) had been mutated ( Supplementary Fig. 5 ). The MYC-335-driven LacZ is expressed in a subset of the tissues where Myc RNA is expressed (Fig. 4, right embryo) .
Correlation between rs6983267 genotype and MYC expression We examined a possible correlation between rs6983267 genotype and MYC expression in lymphoblasts, normal colon epithelial cells and CRCs. Only a marginally significant relationship between genotype and gene-level (16 probesets) expression of MYC was observed in lymphoblasts (empirical Bayes statistics, P ¼ 0.04, not corrected for Chr. 8 position with the highest number of overlapping sequences as determined by ChIP-Seq. rs6983267 resides at the peak. An asterisk depicts a shoulder peak at the other TCF4 site (Fig. 2a) . (f) ChIP followed by PCR and Sanger sequencing for the rs6983267-containing region reveals that TCF4 favors binding to the risk allele of rs6983267 in LoVo cells. Sanger-sequencing of anti-TCF4-precipitated DNA (aTCF4) reveals that the risk allele (G) is enriched by the TCF4 precipitation (bottom panel) compared to input DNA (top panel). (g) Sanger sequencing analysis of G to T nucleotide ratios at rs6983267 site in seven heterozygous cell lines before (light bars) or after (dark bars) anti-TCF4 ChIP. TCF4 preferentially binds to the G allele in all cases.
multiple testing), using publicly available exon array and genotype data from 57 CEU HapMap individuals (see Online Methods). By comparing MYC expression in normal colonic epithelium from 33 GG and 35 TT CRC samples, we observed no significant difference between the groups (P ¼ 0.83, t-test). Similarly, examination of our previously published gene expression data on 34 CRCs did not show a significant dependence between rs6983267 genotype and MYC expression (P ¼ 0.48). Indeed, no correlation between rs6983267 genotype and MYC expression levels has been observed in previous studies by others using lymphoblastoid cell lines 28 and CRCs 8 .
DISCUSSION
Genome-wide association studies are identifying an increasing number of SNPs associated with disease susceptibility. The challenge is to unravel the causative mechanisms related to these variants. The first such study of CRC pinpointed six susceptibility loci: rs6983267 at 8q24 (ref.
3), rs4939827, rs12953717 and rs4464148 at 18q21 (SMAD7) 29 , rs4779584 and rs10318 at 15q 30 , rs3802842 at 11q23 (ref. 17 ), rs10795668 at 10p14 and rs16892766 at 8q23. 3 (ref. 31) . Recent meta-analysis has identified four new susceptibility loci at 14q22 (rs4444235), 16q22 (9929218), 19q13 (rs10411210) and 20p12 (rs961253) 28 . At 8q24, multiple different regions associate with different cancer subtypes, including colorectal 3 , prostate 6, 14 and bladder cancer 32 . The data in our study provide evidence that at least one mechanism involved is the potential to regulate gene expression. In addition to MYC-335, at least one other associated region at 8q24 contains regulatory elements. The region associated with bladder cancer 32 contains the MYC regulatory elements CM3 and CM5, which we identified previously 18 . MYC-335, CM3 and CM5 all have distinct tissue specificities, possibly explaining differences in associated 8q24 regions between cancer types.
The data presented in this study show that rs6983267 affects binding of the Wnt-regulated transcription factor TCF4 in a regulatory element that is functional in CRC cells. TCF4 is a member of a class of closely related Wnt-regulated transcription factors that includes TCF1, TCF3, TCF4 and LEF1. Although TCF4 is thought to be the key transducer of Wnt signals in CRC, it is possible that part of the increased responsiveness to Wnt signaling caused by the G allele of rs6983267 could also be transmitted through these other TCF family members.
The affinity difference between T and G alleles for TCF4 was found to be relatively small, and the magnitude of this effect is in proportion to the slightly increased-but on population level extremely important-CRC risk related to rs6983267 (ref. 10) . Although the similarity of the magnitudes of effect is of note, it is clear that, in general, the size of the biological effect cannot be predicted by the epidemiological risk, or vice versa. It is also important to note that G is the ancestral allele, and in addition to conferring a risk to cancer may have yet unknown favorable effects.
Further work will unravel the target(s) of MYC-335. Despite the fact that we and others have been unable to robustly show association between rs6983267 genotypes and MYC expression, one cannot rule out the possibility that at least one of the targets may be MYC. Some considerations speak in favor of this option. First, MYC is the central oncogene whose expression in CRCs is upregulated by 8q24 amplification, and the simplest hypothesis explaining preferential amplification of the G risk allele is that this allele expresses more MYC. Therefore, its copy number increase would confer a stronger selective advantage to tumor cells than copy number increase of the protective allele T, which is also potentially tumorigenic, albeit slightly less so. Second, MYC is a known target of TCF4, and the MYC-335 element is the strongest TCF4-binding region within 1 Mb of MYC. Third, by generating enhancer LacZ transgenic mouse embryos, we showed that MYC-335 drives gene expression in vivo in a pattern that is compatible with that of Wnt-regulated genes such as Myc. Further evidence for MYC being a target of MYC-335 is provided in the accompanying paper by Freedman and colleagues 33 , in which the rs6983267 region is Genome-wide analysis by ChIP sequencing shows that the rs6983267-containing regulatory element (MYC-335) in the vicinity of the MYC gene is the fourth-highest-ranked conserved TCF4-bound regulatory element in LoVo CRC cells. Ten highest-scoring conserved Tcf4-site-containing regulatory elements (by ChIP-Seq peak height) identified by a combination of genome-wide ChIP-Seq and EEL analyses (human to mouse comparison). Genes located within 500 kb of the elements, height of the ChIP-Seq peak and its chromosomal position (NCBI36), P value (see Online Methods for details) and EEL score are shown. Known Wnt/TCF4 targets are indicated in bold. demonstrated to show long-range interaction with the MYC promoter, indeed suggesting a role for MYC-335 as a distant MYC enhancer. Activation of the Wnt signaling pathway, including TCF4 as the major transcription factor, almost invariably occurs early during development of CRC 16 . This is usually achieved by inactivation of the APC tumor suppressor gene already in colonic adenoma formation, which leads to constitutively activated nuclear b-catenin/TCF4 transcription complex and activation of target gene expression such as MYC 15, 34 . Myc is a crucial mediator of intestinal tumorigenesis in mice, as Myc deletion rescues the effect of Apc deficiency in the mouse intestine 35 . The excess of CRC and adenoma risk associated with the G allele of rs6983267, preferential somatic amplification of this allele during tumorigenesis, and the functional data presented here linking rs6983267 to TCF4 affinity is compatible with the extensive previous work identifying Wnt as a key player in genesis of colonic neoplasia. The possible existence of additional genetic variants at MYC-335 contributing to target gene expression cannot be excluded and should be further investigated. Although the importance of the Wnt pathway as a potential target for rational cancer therapies has been clear 36 , these new results suggest that the same pathway may also have implications for the development of personalized cancer prevention strategies 37 .
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Accession codes. Ensembl: Myc input sequences, ENSG00000136997 and ENSMUSG00000022346. NCBI GEO: exon array used to correlate rs6983267 genotype to MYC expression, GSE9372; gene expression data from this study, GSE4045. 
ONLINE METHODS
SNP array experiments and data analysis. Twelve tumor and matched normal DNAs from the Finnish CRC sample series 43, 44 were hybridized to 24 Illumina HumanCNV370-Duo SNP array chips (Illumina) according to the manufacturer's instructions to examine whether the allelic imbalance in the tumor DNA observed in our previous study 10 was due to allelic loss or gain. CRC samples selected to the SNP arrays represented 60% or more carcinoma cells according to pathologist's evaluation. We analyzed copy number differences between tumors and respective normal samples with the BeadStudio 3.2 CNV Estimator tool using 0.2-Mb window size and 0.01 P-value cutoff.
Imputation and association analyses. Prediction of the untyped SNPs in the case-control datasets of NSCCG1 and CORGI (Supplementary Note) was carried out using MACH1.0 on HapMap (HapMap Data Rel 21a/phase II Jan07 on NCBI B35 assembly, dbSNPb125) phase II data. In total, 172 HapMap SNPs were successfully imputed in the interval between 128.419 Mb and 128.562 Mb at 8q24 using available SNP genotype data from NSCCG1 (83 SNPs) and CORGI (29 SNPs). We verified the integrity of imputed data where possible by crosschecking the concordance of imputed genotypes with that of available Illumina SNP genotype data. Concordance between imputed and directly measured genotypes was high. Specifically, for rs6983267 and rs10505477, concordance was greater than 99.6% (99.9% and 99.7%, respectively), thereby ensuring a high confidence in observations. Statistical analyses were undertaken in Stata Version 8 or R software. Linkage disequilibrium statistics were calculated using Haploview software (v4.0).
In silico methods. To predict conserved enhancer elements, we aligned human and mouse genomic sequences 500 kb up-and downstream from MYC with the EEL algorithm essentially as described 18 . The Myc input sequences (chr. 8:128317498-129322853 and chr.15:61316896-62321907) were extracted from Ensembl database and masked for repetitive sequences using RepeatMasker program. The EEL analysis was run with default parameter values 19 . We used 107 high-quality transcription factor binding profiles were used 18 .
For comparison of EEL results with TCF4 ChIP-Seq, we conducted a genome-scale EEL alignment essentially as described 18 , with the following minor modifications: 160 transcription factor binding matrices (from Jaspar2; refs. 18,45) were used in alignment of 17,330 human genes with their mouse orthologs (from ensembl), including 500 kb of flanking sequences in both directions. Sequences were masked for tandem repeats (trf) and for known exons (ensembl 48). The aligned regions covered 80.6% of the human genome. The EEL alignment was executed with parameters lambda ¼ 1.0, xi ¼ 2684.59, mu ¼ 0.144011 and nu ¼ 2.98355, which were optimized with simulated annealing as previously described (see URLs section below). The binding site motif matrices had pseudocount of total 0.001 added according to the uniform, independent and identically distributed (i.i.d.) background. The sites with motif score (log 2 odds between motif and uniform i.i.d. background) greater than 9 for at least one human haplotype were used in the alignment. The resulting data describing the scores and genomic locations of the predicted enhancer elements and the conserved transcription factor binding sites that they contain were loaded into a relational database. To generate Table 1 , we ranked all TCF4 ChIP-Seq peaks that overlapped with predicted enhancer elements (EEL score 4 300; this cut-off results in identification of approximately one regulatory element per aligned gene) and contained at least one conserved TCF4 site according to the height of the ChIP-Seq peak.
Cell culture. We obtained human CRC cell lines LoVo, HCT15, CCL-231, LS180, LS174T, VACO5, HCT8 and GPD5 from the American Type Culture Collection (ATCC) or the European Collection of Cell Cultures (ECACC). Cell culture was carried out using standard protocols.
Transcription factor binding assay. We conducted a luminescent-based transcription factor binding assay essentially as described 46 , except that we took the 5-bp sequences flanking the TCF4 sites from the flanking sequences of the TCF4 binding site on MYC-335. This method is based on competition between binding sites and measures relative specific DNA-binding affinity of a transcription factor to a given sequence compared to the highest affinity sequence (relative specific affinity of 1) and to scrambled oligonucleotide control (relative specific affinity of 0). The double-stranded, blunt-ended oligonucleotide sequences used are described in Supplementary Table 2 . The method has been extensively validated against EMSA previously using GLI2 and Tcf4 (ref. 18 and data not shown). The TCF4 binding affinity of MYC-335 TCF4 site was normalized as previously described 46 .
Electrophoretic mobility shift assay (EMSA). EMSA was conducted using the LightShift Kit (Pierce). Double-stranded biotinylated TCF-consensus oligonucleotides were incubated for 1 h with control lysate or TCF4-Renilla luciferase fusion protein containing cell lysate 45 in the presence of no competitor or 50-fold molar excess of scrambled, TCF-consensus, G allele or T allele doublestranded competitor oligonucleotides (see Supplementary Table 2 for oligonucleotide sequences). Binding buffer 45 was supplemented with 0.2% Triton X-100, 1% milk powder and 25 ng/ml poly(dI-dC). The resulting complexes were resolved in a 5% nondenaturing PAGE gel, transferred onto membrane and detected using streptavidin-HRP conjugate and a chemiluminescent substrate.
Luciferase reporter assays. MYC-335 elements containing G and T alleles of rs6983267 (1,406 bp) were amplified from genomic DNA of LoVo cells and cloned in front of a chicken delta 1-crystallin minimal promoter driving a firefly luciferase gene 47 (for PCR primers see Supplementary Table 2 ). The second and third nucleotides (AT) in the TCF4 sites were mutated to G and C using site-directed mutagenesis, resulting in mutant TCF4 sites GGCGAAAGG and GGCGAAAGT for the G and T allele, respectively. These mutations in TCF4 site completely abolish calculated binding affinity of TCF4 and the same nucleotides are also mutated in the FOPflash Wnt pathway negative control luciferase reporter plasmid. The constructs were fully sequenced and found to harbor three additional variant bases naturally occurring in LoVo, mapping outside the enhancer element. The presence of unintentionally introduced mutations was excluded. The reporters containing the 1,406-bp element were transfected into human HEK293T cells together with a Renilla luciferase control reporter. Where indicated, 20 mM LiCl was added after 24 h to induce Wnt pathway activity. Luciferase activities were measured at 32 h with the DualLuc kit (Promega). We calculated relative luciferase activities by dividing the firefly luciferase counts with the Renilla controls, and the results were normalized to the T allele without Wnt pathway induction. We controlled for the induction of Wnt pathway by LiCl by performing a parallel experiment using the SuperTOPflash Wnt pathway reporter. This reporter showed approximately 1,000-fold induction under these conditions (data not shown).
Chromatin immunoprecipitation (ChIP). We carried out ChIP essentially as described 48 . CRC cells were cross-linked with 1% formaldehyde in PBS at room temperature for 10 min, and reaction was stopped with 125 mM glycine.We collected the cells by centrifugation, isolated nuclei with hypotonic lysis buffer (1 mM EDTA, 10 mM KCl, 20 mM Hepes pH 7.9, 10% glycerol, 1 mM DTT with protease inhibitors) and lysed and sonicated cells in lysis buffer (0,1% SDS, 0,1% sodium deoxycholate, 1 mM EDTA, 10 mM TrisHCl pH 8.0, 140 mM NaCl, 1% Triton X-100 with protease inhibitors) to generate chromatin fragments of 100-400 bp in length. The fragmented chromatin material was clarified by centrifugation and pre-cleared with protein A-agarose beads, followed by immunoprecipitation with antibodies to TCF-4 (Mouse Anti-TCF-4 Monoclonal Antibody, Clone 6H5-3 Exalpha Biologicals), b-catenin (Rabbit Polyclonal Antibody: H-102, Santa-Cruz Biotechnology) or control IgG (normal mouse IgG: sc-2025 or normal rabbit IgG: sc-2027, Santa-Cruz Biotechnology). The precipitates were heat-treated to reverse the formaldehyde cross-links, followed by proteinase K and RNase A treatment, phenol-extraction and ethanol-precipitation. We assessed enrichment of immunoprecipitated material relative to the input material using PCR and gel electrophoresis, as well as quantitative real-time PCR. Allele-specific binding of TCF4 to the rs6983267-containing site was scored by comparing the height of the T and G peaks in sequencing tracts. This method was calibrated by PCR with different ratios of GG and TT DNAs and two distinct set of primers were used to confirm the results. Fold changes were calculated relative to IgG control. For primer sequences for the rs6983267 and negative and positive control regions, see Supplementary Table 2 .
For ChIP-by-sequencing, the precipitated DNA was repaired using Klenow and T4 DNA polymerases and T4 polynucleotide kinase (MBI Fermentas, Latvia), and ligated to adapters according to manufacturer's instructions (Illumina). Subsequently, PCR-amplified fragments of approximately 130-150 bp were sequenced using Illumina Genome Analyzer (Uppsala University and University of Helsinki). Sequencing reads (30 bp or 36 bp) were mapped to the human genome (NCBI36) using Maq software by H. Li, version 0.6.5. Only high-quality reads that could be reliably mapped (mapping quality score at least 30) were accepted, resulting in a total of 13.1 and 7.3 million reads from TCF4 LoVo ChIP and IgG control samples, and 4.1 and 4.4 million reads from GP5D TCF4 ChIP and IgG control samples. Each read was then extended to a sequence of 130 bp, and height was determined at each position as the number of overlapping sequences. This analysis yields a maximum peak width of 250 bp for one occupied TCF4 site (120 bp in both directions from approximately 10 bp site). The positions with a height of 10 or more were defined as peaks. For each peak, the total number of sequences in the continuous region of four or more overlapping sequences was compared to the number of sequences in the same region in the IgG control. The probability of observing the difference between the sequence counts in the ChIP sample and IgG control by chance was estimated using Winflat program 49 . The program was originally developed for digital gene expression analysis and it can take into account the uncertainty associated to low sequence counts and the difference in the total amount of ChIP and IgG control reads. In total, we observed 558 TCF4 peaks in LoVo and 1694 peaks in GP5D with a height of Z10 and P o 0.05.
Mouse embryo analyses. Regulatory element analyses in transgenic mouse embryos and in situ hybridizations were carried out essentially as described 18 . To create the LacZ reporter construct, a 1,193-bp genomic fragment including the rs6983267[G] containing regulatory element was PCR-amplified with Phu polymerase (Finnzymes) from mouse BAC clone and cloned into pTKPD vector (for primers, see Supplementary Table 2) . A mutant construct with two mutated TCF4 sites (GATGAAAGG -GATGAGGGG, AATCAAAGG -AATCAGGGG) was generated with PCR mutagenesis. The constructs were sequenced to verify the sequence and orientation of the inserts. The primers used to generate the Myc in situ hybridization probe are described in Supplementary Table 2 .
Microarray gene expression analysis. We exampled possible correlation of the rs6983267 genotype to MYC expression in lymphoblasts using publicly available exon array (see Accession codes section in Methods, HuEx-1_0-st-v2, Affymetrix) and genotype data from 57 CEU HapMap individuals 50, 51 . Probe-level signals were background-corrected using the on chip antigenomic background probe group and normalized using sketch quantile normalization. Probeset and transcript cluster level signal intenstiy estimates were generated using PLIER. The extended level probeset grouping was used to construct transcript clusters. All preprocessing steps were carried out using Affymetrix Power Tools (APT). We excluded probesets that were not significantly different (P 4 0.05) from the background signal in at least 50% of the samples within each group. This latter signal used the DABG value calculated by PLIER. Association between genotype and signal intensity levels of the probesets or transcript clusters was carried out using linear modelling implemented in Limma package in R 52 . The correlation between technical replicates was estimated and taken into account in the analyses. P values were produced with empirical Bayes statistics.
Gene expression profiles of 34 CRCs, created using Affymetrix HG-U133A 53 , were used for studying the possible correlation between the genotype of the SNP and expression of MYC. The distribution of the genotypes among the samples was 11 with GG, 16 GT and 7 TT. The gene expression data are available in Gene Expression Omnibus (see Accession codes section in Methods). GCRMA pre-processing using CDF-files customized for Ensembl genome database was performed 54 , after which probe set ENSG00000136997_at was used in the analysis. We examined the association between the SNP genotype and expression of MYC by linear regression, using R software.
